Ann: Application for quotation of securities - NEU, page-9

Vesting condition for the incentive have been met. A well deserved reward for the Neuren employees if you ask me

from the annoucment dated 03/02/2022

Material terms:- Exercise price ($3.46 per share) is the volume weighted average price (VWAP) at which the Company's shares weretraded on the ASX in the 5 days preceding the date of issue of the Options.
- Vested options may be exercised no earlier than 1 year after the issue date.
- All options lapse 4 years after the issue date.
- Options are subject to the following vesting conditions:
(a) when the Company determines to progress NNZ-2591 to a Phase 2b or Phase 3 clinical trial following a positive Phase2 clinical trial outcome, or executes a partnering transaction for NNZ-2591;
(b) when the Company executes a partnering transaction for trofinetide outside North America, or submits a MarketingAuthorisation Application for trofinetide in the European Union, the United Kingdom or Japan.
(c) on acceptance by the US FDA of the filing of a New Drug Application for trofinetide.- The options carry no entitlement to vote or participate in new issues.